NVX-CoV2372 / Novavax - LARVOL DELTA

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=21 | Completed | Sponsor: University of Wisconsin, Madison | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Sep 2024 | Trial primary completion date: Mar 2025 ➔ Apr 2024

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old. (PubMed, J Infect) - "All vaccines were immunogenic with more rapid waning after mRNA vaccines. These data support boosting with vaccines with greater specificity for circulating Omicron subvariants."

Journal • Infectious Disease • Novel Coronavirus Disease

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=21 | Active, not recruiting | Sponsor: University of Wisconsin, Madison | Suspended ➔ Active, not recruiting | N=120 ➔ 21

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=120 | Suspended | Sponsor: University of Wisconsin, Madison | Trial completion date: Sep 2024 ➔ Mar 2025 | Recruiting ➔ Suspended | Trial primary completion date: Sep 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease • Novel Coronavirus Disease

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Wisconsin, Madison

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Wisconsin, Madison | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: University of Wisconsin, Madison

New P2 trial • Infectious Disease • Novel Coronavirus Disease • IFNG